Clinical Trial Update: Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the impact of rimonabant on regression of asymptomatic cardiovascular damage was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Microalbuminuria
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Obesity, Microalbuminuria | Phase 3 | Status: TERMINATED